SCHEMBL18601145

SCHEMBL18601145

C[C@H]1Nc2ccccc2C[C@H]1C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.60
MAPT P10636 1/20 0.60
BRD4 O60885 4/20 0.42
CREBBP Q92793 3/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MMP3 P08254 1/20 0.39
MMP8 P22894 1/20 0.39
MTNR1A P48039 3/20 0.38
MTNR1B P49286 1/20 0.38
ALDH1A1 P00352 1/20 0.37
EPHX2 P34913 1/20 0.37
TSHR P16473 1/20 0.37
EP300 Q09472 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.35
NOTUM Q6P988 1/20 0.35
AR P10275 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22231618 0.81 GAA (0.62) GAAMAPTBRD4CREBBPMEN1
SCHEMBL19055467 0.79 MAPT (0.44) GAAMAPTBRD4MEN1KMT2A
SCHEMBL19055468 0.79 MAPT (0.44) GAAMAPTBRD4MEN1KMT2A
SCHEMBL17215681 0.78 EPHX2 (0.50) GAAMAPTBRD4CREBBPMEN1
SCHEMBL4271424 0.77 GAA (0.60) GAAMAPTBRD4CREBBPMTNR1A
SCHEMBL7027229 0.76 MAPT (0.55) GAAMAPTBRD4CREBBPMEN1
Methyl Alcohol SCHEMBL27493922 0.76 GAA (0.93) GAAMAPTBRD4CREBBPMTNR1A
Hydrochloric Acid SCHEMBL8115356 0.75 GAA (0.58) GAAMAPTBRD4CREBBPMTNR1A
SCHEMBL16169476 0.75 GAA (0.49) GAAMAPTBRD4CREBBPMTNR1A
SCHEMBL91080 0.75 GAA (1.00) GAAMAPTBRD4CREBBPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10442798-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-10-15 US disclosed
US-10364237-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-07-30 US disclosed
US-20180265502-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE LYCERA CORPORATION 2018-09-20 US disclosed
US-20180208587-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE LYCERA CORPORATION 2018-07-26 US disclosed
US-9896441-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2018-02-20 US disclosed
US-20170183331-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-06-29 US disclosed
EP-3140291-A2 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE Lycera Corporation (US) 2017-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180265502-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE RORA, RORB, RORC GAA 2478/4885MAPT 2550/4885BRD4 550/4885
US-10364237-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease RORA, RORC, RORB GAA 2567/4885MAPT 3295/4885BRD4 436/4885
US-10442798-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease RORA, RORC, RORB GAA 2567/4885MAPT 3295/4885BRD4 436/4885
US-20170183331-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE RORA, RORB, RORC GAA 2478/4885MAPT 2550/4885BRD4 550/4885
US-20180208587-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE RORA, RORB, RORC GAA 2478/4885MAPT 2550/4885BRD4 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.